Brands, Medical Use, Clinical Data
- Anti-Anxiety Agents
- Adjuvants, Anesthesia
- GABA Modulators
- Tablet (0.125 mg, 0.25 mg)
Brands / Synonyms
Alti-Triazolam; Apo-Triazo; Clorazolam; DEA No. 2887; Gen-Triazolam; Halcion; Novidorm; Novo-Triolam; Novodorm; Songar; Triazolam; Triazolam 100 ug/mL in Methanol; Triazolam [Usan:Ban:Inn:Jan]; Triazolamum [Inn-Latin]
For the short-term treatment of insomnia.
A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.
Mechanism of Action
Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.
Biotrnasformation / Drug Metabolism
Hepatic. Small amounts of unmetabolized triazolam appear in the urine.
Triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other
Benzodiazepines may cause fetal damage when administered during pregnancy. An increased risk of congenital
malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has
been suggested in several studies. Transplacental distribution has resulted in neonatal CNS depression following the
ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy.
Triazolam is contraindicated in pregnant women. If there is a likelihood of the patient becoming pregnant while
receiving triazolam, she should be warned of the potential risk to the fetus. Patients should be instructed to
discontinue the drug prior to becoming pregnant. The possibility that a woman of childbearing potential may be
pregnant at the time of institution of therapy should be considered.
HALCION is contraindicated with ketoconazole, itraconazole, and nefazodone, medicat ions that significantly impair
the oxidative metabolism mediated by cytochrome P450 3A (CYP 3A).
Both pharmacodynamic and pharmacokinetic interactions have been reported with benzodiazepines. In particular,
triazolam produces additive CNS depressant effects when coadministered with other psychotropic medications,
anticonvulsants, antihistamines, ethanol, and other drugs which themselves produce CNS depression.
Drugs that inhibit triazolam metabolism via cytochrome P450 3A: The initial step in triazolam
metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A). Drugs which inhibit this metabolic pathway may
have a profound effect on the clearance of triazolam .
Drugs and other substances demonstrated to be CYP 3A inhibitors of possible clinical significance on the
basis of clinical studies involving triazolam (caution is recommended during coadministration with
IsoniazidóCoadministration of isoniazid increased the maximum plasma concentration of triazolam by
20%, decreased clearance by 42%, and increased half-life by 31%.
Oral contraceptivesóCoadministration of oral contraceptives increased maximum plasma concentration
by 6%, decreased clearance by 32%, and increased half-life by 16%.
Grapefruit juiceóCoadministration of grapefruit juice increased the maximum plasma concentration
of triazolam by 25%, increased the area under the concentration curve by 48%, and increased half-life by 18%.
Drugs demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines
metabolized similarly to triazolam or on the basis of in vitro studies with triazolam or other benzodiazepines
(caution is recommended during coadministration with triazolam): Available data from clinic a l studies of
benzodiazepines other than triazolam suggest a possible drug interaction with triazolam for the following:
fluvoxamine, diltiazem, and verapamil. Data from in vitro studies of triazolam suggest a possible drug interact ion
with triazolam for the following: sertraline and paroxetine. Data from in vitro studies of benzodiazepines other than
triazolam suggest a possible drug interaction with triazolam for the following: ergotamine, cyclosporine, amiodarone,
nicardipine, and nifedipine. Caution is recommended during coadministration of any of these drugs with triazolam.
Drugs that affect triazolam pharmacokinetics by other mechanisms:
RanitidineóCoadministration of ranitidine increased the maximum plasma concentration of triazolam
by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%. Caution is
recommended during coadministration with triazolam.